HC Wainwright & Co. Maintains Buy on Gracell Biotechnologies, Raises Price Target to $13
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Emily Bodnar maintains a 'Buy' rating on Gracell Biotechnologies (NASDAQ:GRCL) and raises the price target from $12 to $13.
August 14, 2023 | 4:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Gracell Biotechnologies' price target has been raised from $12 to $13 by HC Wainwright & Co. The firm maintains a 'Buy' rating on the stock.
The raised price target indicates that the analyst sees potential for the stock's price to increase. This, coupled with the maintained 'Buy' rating, suggests a positive outlook for the stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100